Will Nintedanib be included in medical insurance in 2023?

Nintedanib (Nintedanib) has been approved by the State Food and Drug Administration in 2022 for domestic marketing, and subsequently entered Class B medical insurance through relevant policies of the National Medical Insurance Administration, limited to idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-related interstitial lung disease (SSc-ILD) will be reimbursed. The generic name is nintedanib ethanesulfonate soft capsules, specificationsThe price of 150mg*30 capsules per box may be more than 4,000 yuan. For specific reimbursement ratios, please consult the local medical insurance bureau or hospital.

Nintedanib is the only drug approved to be taken twice daily to treat adults with a lung disease called idiopathic pulmonary fibrosis (IPF) and to treat adults with long-term (chronic) interstitial lung disease whose pulmonary fibrosis continues to get worse (progression), and is also used to slow systemic sclerosis The most common side effects of nintedanib are diarrhea, nausea, stomach pain, vomiting, liver problems, decreased appetite, headache, weight loss, and high blood pressure.

Nintedanib Original drug available overseas has Turkish version and Indian version, specificationsThe price of 150mg*60 capsules per box may be more than 5,000 RMB (the price may fluctuate due to the exchange rate). There are also nintedanib generic drugs produced overseas in other countries. For example, the price of 150mg*30 capsules produced by BDR Pharmaceutical Factory in India may be several hundred yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad.